Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
https://www.zacks.com/stock/news/2215085/biotech-stock-roundup-gild-down-on-study-results-inbx-gains-on-sanofi-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2215085
Jan 24, 2024 - Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
0
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214518
Jan 23, 2024 - Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
0
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2212109/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2212109
Jan 18, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
Top Stock Reports for Adobe, IBM & Sanofi
https://www.zacks.com/commentary/2211323/top-stock-reports-for-adobe-ibm-sanofi?cid=CS-ZC-FT-research_daily-2211323
Jan 17, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), International Business Machines Corporation (IBM) and Sanofi (SNY).
0
IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why
https://www.zacks.com/stock/news/2210645/igm-bio-igms-stock-rallies-142-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2210645
Jan 16, 2024 - IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.
0
Sanofi (SNY) Presents at J.P. Morgan 42nd Annual Healthcare Conference Call Transcript
https://seekingalpha.com/article/4662029-sanofi-sny-presents-j-p-morgan-42nd-annual-healthcare-conference-call-transcript?source=feed_sector_transcripts
Jan 09, 2024 - Sanofi (NASDAQ:NASDAQ:SNY) J.P. Morgan 42nd Annual Healthcare Conference Call January 9, 2024 1:30 PM ETCompany ParticipantsPaul Hudson - Chief Executive...
0
Top Research Reports for Meta Platforms, Broadcom & Verizon
https://www.zacks.com/commentary/2206970/top-research-reports-for-meta-platforms-broadcom-verizon?cid=CS-ZC-FT-research_daily-2206970
Jan 09, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Broadcom Inc. (AVGO) and Verizon Communications Inc. (VZ).
0
Warning: SNY is at high risk of cutting its dividend
https://seekingalpha.com/warnings/4052831-warning-sny-is-high-risk-of-cutting-dividend?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Jan 07, 2024 - Sanofi (NASDAQ:SNY) has displayed warning signs that have historically led to dividend cuts. The company has a Dividend Safety Score of F.
0
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-lly-s-new-digital-pharmacy-nvo-abbv-s-fresh-r-d-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2206363
Jan 05, 2024 - Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
0
Here's Why Sanofi (SNY) is a Strong Value Stock
https://www.zacks.com/stock/news/2204141/here-s-why-sanofi-sny-is-a-strong-value-stock?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2204141
Jan 01, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
<Page 2